Travere Therapeutics' Kidney Disease Drug Falls Short in Trial, Stock Plunges
TL;DR
Travere Therapeutics' kidney disease drug, Filspari, narrowly missed meeting the key endpoint in its confirmatory study, which measured kidney function. Despite this setback, the company still plans to apply for full approval of Filspari in IgA nephropathy next year. The study results will now be evaluated by the FDA, who will decide whether to withdraw the drug. The stock of Travere Therapeutics plummeted following the news.
Topics:businesshealthcare#confirmatory-study#filspari#healthcare#kidney-disease-drug#stock-plummet#travere-therapeutics
- Travere Therapeutics just misses on confirmatory study for kidney disease drug, stock plummets Endpoints News
- Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial MarketWatch
- Why Shares of Travere Therapeutics Are Slumping Thursday The Motley Fool
- Drug for rare kidney disease narrowly misses mark in clinical trial STAT
- Travere's Filspari misses the mark in key trial, but market removal looks unlikely: analysts FiercePharma
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News